Creating new topical treatments for psoriasis
Official title: Development of Novel Topical Therapeutics for Psoriasis
Funded at Biotherapeutics, INC. · NIH-10698601 · Data updated 2026-11-12
This study is working on new skin treatments for psoriasis that aim to be safer and more effective, helping people with this condition feel better by improving how skin and immune cells interact.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biotherapeutics, INC. NIH-funded |
| Lab location | 1 site (Blacksburg, United States) |
| Project start | September 5, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $295,924 |
| NIH project number | 1R43AR082756-01 |
| Project ID | NIH-10698601 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from psoriasis who are seeking more effective treatment options.
✕Less likely to help
Patients with psoriasis who are currently satisfied with their existing treatments may not find additional benefit from this research.
What this research studies
This research focuses on developing innovative topical therapies specifically for psoriasis, a chronic autoimmune condition affecting millions. The approach combines advanced computational modeling with experimental methods to create safer and more effective treatment options. Current treatments often have limited efficacy and significant side effects, leading to a need for new solutions. The goal is to create a first-in-class therapeutic that targets the interaction between skin cells and immune cells to improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could provide patients with safer and more effective topical treatments for psoriasis, reducing side effects and improving quality of life.
How similar studies have gone: Other research has shown promise in developing novel therapies for psoriasis, but this specific approach is innovative and aims to address unmet clinical needs.
Where this research is happening
-
Biotherapeutics, INC.
Blacksburg, United States Active
Researchers
- Principal investigator: Tubau Juni, Nuria — Biotherapeutics, INC.
- Study coordinator: Tubau Juni, Nuria
Related research
Other NIH-funded projects on the same topics.
-
Testing antiplatelet approaches in psoriasis to improve blood vessel health
A study at NYU School of Medicine will test antiplatelet strategies to reduce heart and blood vessel risk in adults with psoriasis.
-
Topical immunoregulatory therapy for psoriasis
A new topical treatment for psoriasis is being developed to safely reduce skin symptoms and improve quality of life.
-
Understanding psoriasis genetic signals across diverse populations
A study to uncover the genetic factors behind psoriasis in African American people using advanced genomic and epigenetic methods.
-
SerpinB3 and keratinocytes: a new path to understanding psoriasis
This NIH grant explores how a keratinocyte protein called SerpinB3 may drive plaque psoriasis, with the hope of finding new treatments for people with moderate-to-severe disease.
-
Role of a skin protein in psoriasis-related diabetes
A study explores how a skin inflammation signal may contribute to developing type 2 diabetes in people with psoriasis.
-
How satisfied people with plaque psoriasis are with their treatments
This project will try a new questionnaire called DermSat to measure treatment satisfaction among people with plaque psoriasis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.